NCT03669393View on ClinicalTrials.gov

A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 18, 2018

Primary Completion Date

November 22, 2019

Study Completion Date

November 22, 2019

Conditions
Retinal TelangiectasisIdiopathic Juxtafoveal Retinal Telangiectasia
Interventions
DRUG

THR-317 8mg

3 intravitreal injections of THR-317 8mg, approximately 1 month apart

Trial Locations (3)

1000

Hôpital Ophtalmique Jules-Gonin, Lausanne

75010

Hôpital Lariboisière, Paris

75181

Hôpital Cochin, Paris

Sponsors

Lead Sponsor

ThromboGenics
All Listed Sponsors
lead

ThromboGenics

INDUSTRY